Advertisement
Screener

GAIN THERAPEUTICS, INC (GANX) Payments to Acquire Productive Assets

2.8 / 5 stars · 68/120 Roast Me

GAIN THERAPEUTICS, INC Payments to Acquire Productive Assets

GAIN THERAPEUTICS, INC (GANX) reported Payments to Acquire Productive Assets of $22.49 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-03-26

  • GAIN THERAPEUTICS, INC payments to acquire productive assets for the quarter ending 2024-12-31 was $945.00, a 4873.68% increase year-over-year.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for the quarter ending 2024-09-30 was $1.00, a 99.85% decline year-over-year.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for the quarter ending 2023-12-31 was $19.00, a 99.80% decline year-over-year.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for the quarter ending 2023-09-30 was $650.00, a 98.86% decline year-over-year.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for fiscal 2024 was $22.49K, a 46.46% increase from fiscal 2023.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for fiscal 2023 was $15.36K, a 87.09% decline from fiscal 2022.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for fiscal 2022 was $118.95K, a 26.26% increase from fiscal 2021.
  • GAIN THERAPEUTICS, INC payments to acquire productive assets for fiscal 2021 was $94.21K.
Period endPayments to Acquire Productive Assets 3 monthPayments to Acquire Productive Assets 6 monthPayments to Acquire Productive Assets 9 monthPayments to Acquire Productive Assets 12 month
2024-12-31$945.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$946.00
derived: sum of 2 quarters · filed 2026-03-26
$22.49K
10-K · filed 2026-03-26
2024-09-30$1.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$21.55K
10-Q · filed 2025-11-12
2024-06-30$21.55K
10-Q · filed 2025-08-12
2023-12-31$19.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$669.00
derived: sum of 2 quarters · filed 2025-03-27
$4.31K
derived: sum of 3 quarters · filed 2025-03-27
$15.36K
10-K · filed 2025-03-27
2023-09-30$650.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$4.29K
derived: sum of 2 quarters · filed 2024-11-14
$15.34K
10-Q · filed 2024-11-14
$24.74K
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$3.64K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$14.69K
10-Q · filed 2024-08-08
$24.09K
derived: sum of 3 quarters · filed 2024-08-08
$81.27K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$11.04K
10-Q · filed 2024-05-14
$20.44K
derived: sum of 2 quarters · filed 2024-05-14
$77.62K
derived: sum of 3 quarters · filed 2024-05-14
$122.17K
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$9.40K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26
$66.58K
derived: sum of 2 quarters · filed 2024-03-26
$111.13K
derived: sum of 3 quarters · filed 2024-03-26
$118.95K
10-K · filed 2024-03-26
2022-09-30$57.18K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$101.73K
derived: sum of 2 quarters · filed 2023-11-14
$109.56K
10-Q · filed 2023-11-14
2022-06-30$44.55K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$52.38K
10-Q · filed 2023-08-10
2022-03-31$7.83K
10-Q · filed 2023-05-12
2021-12-31$94.21K
10-K · filed 2023-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lifevantage Corp (LFVN)United States$0.078B15.40
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94
Telomir Pharmaceuticals, Inc. (TELO)United States$0.084B
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B